Edito

Dear colleagues, patients, families, and caregivers, 

We are pleased to announce the 4th Global Congress on Sickle Cell Disease will convene in Paris on June 16-18, 2022. Partners of the Club du Globule Rouge et du Fer, the French Society of Hematology, the European Hematology Association, and the University of Paris.

Sickle cell disease is one the world’s most prevalent genetic diseases.  Major advances have been made in understanding the disease, paving the way for new and effective treatments. Neonatal screening is developing in many countries, resulting in early prevention of infections and improved parental education. New preventive treatments for vaso-occlusive crises and chronic anemia are now available.

Hydroxyurea has proven clinical efficacy in preventing pain and vaso-occlusive events. Cure of the disease is now possible thanks to hematopoietic stem cell transplant and gene therapy. Nevertheless, life expectancy and quality of life remain significantly degraded for the majority of patients. Access to safe transfusion and hydroxyurea is still limited in many countries. Education must be intensified; psychological and social supports are needed. It is of paramount importance that we share knowledge and experience, while strengthening links between communities affected by sickle cell disease. The 4th Global Congress on Sickle Cell Disease will feature high-level scientific and state-of-the-art presentations, combined with patient testimonies and workshops. 

We  look forward to welcoming you in the beautiful city of Paris.

Isaac Odame 
Mariane de Montalembert